BSI SA
VC Fund
Lugano, Switzerland
BSI SA is a VC fund in Lugano focused on Biopharma and Health Care. BSI SA provides asset management and related services to private and institutional clients in Switzerland and internationally. The company offers services relating to asset management, including investment funds; placing of fiduciary deposits; and trading in currencies and securities, precious metals, and foreign exchange. Its services includecorporate finance services, such as services for mergers and acquisitions, capital markets, and business evaluations; and life insurance solutions as an agent. The company also offers financial planning, advisory, and credit services. As of December 31, 2008, it operated through a network of seven branches in Switzerland; seven representative offices in Athens, Buenos Aires, Hong Kong, Montevideo, Panama, Taipei, and Bahrain; and six banks in Bahamas, Luxembourg, Madrid, Monte Carlo, Paris, and Singapore. The company was founded in 1873 and is headquartered in Lugano, Switzerland. BSI SA operates as a subsidiary of Participatie Maatschappij Graafschap Holland N.V.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries BSI SA invests in
Stages BSI SA invests in
Countries BSI SA invests in
Investment Focus
Industry
- Biopharma 1 (50%)
- Health Care 1 (50%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
GlobeImmune
|
GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediatedcancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado. | $17.5M / Series E / Jan 19, 2010 | |
Telormedix
|
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. | $19M / Series A / Sep 30, 2008 |
Co-Investors
Aravis Ventures
1 deal together
Generali Financial Holding
1 deal together
Nextech Invest
1 deal together
ProQuest Investments
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does BSI SA invest in?
BSI SA invests primarily in Biopharma, Health Care and Therapeutics startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did BSI SA last invest?
The most recent investment recorded for BSI SA closed in Jan 2010. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
